International consensuses and guidelines on diagnosing and managing cytomegalovirus (CMV) retinitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Professors of Ophthalmology (AAPPO) and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII)
Asia-Pacific Journal of Ophthalmology · 2025-09 · 14 (5) · 100248
DOI: 10.1016/j.apjo.2025.100248 ↗Kurz gefasst
Leitlinie in der Zeitschrift Asia-Pacific Journal of Ophthalmology, 2025-09. Verfasst von De-Kuang Hwang und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Ophthalmology, Taipei Vetera…. Hauptthemen laut MEDLINE: Cytomegalovirus Retinitis, Antiviral Agents, Societies, Medical, Ophthalmology. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Hospital Authority, Beijing Nova Program, Chinese University of Hong Kong.
Abstract (Originalsprache)
With the paradigm changes in antiviral therapy, there are a myriad of emerging controversies in the management of cytomegalovirus retinitis (CMVR). A certain extent of variability exists in the management of CMVR among clinical practices worldwide. Hence, alignment in the management strategy is important towards optimizing the care of CMVR. An international panel of experts (IPE) formulated consensus statements for CMVR regarding to its 1) diagnosis, 2) screening, 3) treatment, 4) management in special populations and 5) emerging technologies. The clinical diagnosis of CMVR relies on patient's susceptibility due to compromised immune function and characteristic fundus manifestations. Polymerase chain reaction (PCR) of intraocular fluid for detection of CMV is indicated when confirmation is necessary. Oral valganciclovir is the preferred first-line treatment, and intravitreal ganciclovir injection when CMVR threatens to involve the posterior pole. Cessation of maintenance treatment can be considered after 6 months when CMVR remains inactive with immune reconstitution. Immune recovery uveitis (IRU) must be distinguished from CMVR relapse. Screening is recommended for high risk cases. Utilization of telemedicine and artificial intelligence-aided interpretation will help to alleviate the resources required for CMVR screening. Evidence for novel antiviral and immunotherapy have been appraised as second-line treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan.
- Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong.
- Beijing GIANTMED Medical Diagnostics Lab, Beijing, China; Department of Ophthalmology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore; Department of Ophthalmology, National Healthcare Group Eye Institute, Tan Tock Seng Hospital, Singapore; Singapore Eye Research Institute,…
- Singapore Eye Research Institute, Singapore; Singapore National Eye Center, Singapore; Ophthalmology & Visual Sciences Academic Clinical Program, Duke-NUS Medical School, Singapore.
- Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Förderung
- Beijing Hospital Authority
- Beijing Nova Program
- Chinese University of Hong Kong
Zitieren
APA
Hwang, D. K., Ng, D. S. C., Qian, Z., Agrawal, R., Chan, A. S. Y., Chhablani, J., Choopong, P., Gupta, V., Invernizzi, A., McCluskey, P., Lee, C. S., Natarajan, S., La Distia Nora, R., Ocampo, V. V., Singh, R., Somkijrungroj, T., Sonoda, K. H., Wei, W., Wong, I. Y. H., …, & Tao, Y. (2025). International consensuses and guidelines on diagnosing and managing cytomegalovirus (CMV) retinitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Professors of Ophthalmology (AAPPO) and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII). Asia-Pacific Journal of Ophthalmology, 14(5), 100248. https://doi.org/10.1016/j.apjo.2025.100248
Vancouver
Hwang DK, Ng DSC, Qian Z, Agrawal R, Chan ASY, Chhablani J, et al. International consensuses and guidelines on diagnosing and managing cytomegalovirus (CMV) retinitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Professors of Ophthalmology (AAPPO) and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII). Asia-Pacific Journal of Ophthalmology. 2025;14(5):100248. doi:10.1016/j.apjo.2025.100248
BibTeX
@article{Hwang2025,
author = {Hwang, De-Kuang and Ng, Danny S C and Qian, Zhuyun and Agrawal, Rupesh and Chan, Anita S Y and Chhablani, Jay and Choopong, Pitipol and Gupta, Vishali and Invernizzi, Alessandro and McCluskey, Peter and Lee, Christopher Seungkyu and Natarajan, Sundaram and La Distia Nora, Rina and Ocampo, Vicente Victor and Singh, Ramandeep and Somkijrungroj, Thanapong and Sonoda, Koh-Hei and Wei, Wenbin and Wong, Ian Y H and Lam, Dennis S C and Tao, Yong},
title = {International consensuses and guidelines on diagnosing and managing cytomegalovirus (CMV) retinitis by the Asia-Pacific Vitreo-retina Society (APVRS), the Asia-Pacific Professors of Ophthalmology (AAPPO) and the Asia-Pacific Society of Ocular Inflammation and Infection (APSOII)},
journal = {Asia-Pacific Journal of Ophthalmology},
year = {2025},
volume = {14},
number = {5},
pages = {100248},
doi = {10.1016/j.apjo.2025.100248}
}
EUVIMED